IL6 and neoplasm: IL-6/JAK2/STAT3 signaling can down-modulate the antitumor immunity of tumor-infiltrating immune cells because STAT3 negatively regulates the functions of neutrophils, natural killer (NK) cells, effector T cells, and dendritic cells.